ArticleBMC pulmonary medicine2025
Prognostic role of pretreatment serum α-hydroxybutyrate dehydrogenase in patients with small cell lung cancer.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe role of pretreatment serum α-hydroxybutyrate dehydrogenase (α-HBDH) in small cell lung cancer (SCLC) prognosis prediction remains unknown. We sought to investigate the influence of pretreatment α-HBDH level on the survival of patients with SCLC.
methodsThe serum concentration of α-HBDH was measured in 400 SCLC patients. The correlations between pretreatment serum α-HBDH concentration and clinicopathological characteristics were analysed. Univariate and multivariate Cox regression analyses were used to evaluate the relationships between α-HBDH levels and the progression-free survival (PFS) and overall survival (OS) of SCLC patients.
resultsPretreatment α-HBDH levels were closely associated with tumour stage, NSE levels, LDH levels, and surgical treatment. Patients with high α-HBDH were more likely to have extensive disease, high NSE levels, and high LDH levels (< 250 vs. ≥ 250 U/L, 13.0% vs. 94.8%) and were less likely to have surgery (p < 0.005 for all). Multivariate analysis revealed that tumour stage, tumour size, chemotherapy plus surgery, pretreatment α-HBDH, NSE, and LDH were associated with OS in SCLC patients. Patients in the high α-HBDH group had a 33.9% greater risk of death than patients in the normal α-HBDH group did [HR 1.339; 95% CI: 1.070-1.674]. Patients with high α-HBDH had worse OS than patients with normal α-HBDH did (median OS, 10.0 vs. 15.0 months).
conclusionsElevated pretreatment serum α-HBDH is independently associated with poor OS in SCLC patients. The potential of HBDH as a complementary marker for the prediction of SCLC survival warrants further investigation in conjunction with other indicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.